Top in hem/onc: Nut consumption and cancer survival, earlier mammograms in Black women
Click Here to Manage Email Alerts
Recent data revealed that regular peanut and tree nut consumption was associated with higher survival rates among long-term breast cancer survivors, particularly those with higher total energy intake and early-stage cancer.
A report on the data was the top story in hematology/oncology last week.
Another top story was about the potential benefits of earlier breast cancer screening in Black women. Researchers estimated that biennial screenings starting at 40 years of age could reduce breast cancer-associated mortality by 57%.
Read these and more top stories in hematology/oncology below:
Nut consumption associated with survival benefit among long-term breast cancer survivors
Nut consumption appeared to be associated with higher survival rates among long-term breast cancer survivors and should be emphasized as a modifiable lifestyle factor in survivor guidelines, according to a study in International Journal of Cancer. Read more.
Earlier breast cancer screening for Black women could reduce mortality disparities
Establishing biennial mammography screening beginning at age 40 years could reduce breast cancer-associated mortality by 57% among Black women, according to study results published in Annals of Internal Medicine. Read more.
Fear of recurrence ‘almost universal’ among cancer survivors
For individuals who have survived cancer and endured its treatment, the threat of recurrence may never entirely fade away. Read more.
Cancer experts offer guidance on COVID-19 vaccination for patients with blood cancer
A collaborative team of cancer experts from leading academic institutions and organizations has released recommendations for optimal protection against COVID-19 among individuals with blood cancer. Read more.
Personalized interventions reduce chemotherapy-related toxicity among older adults
Use of personalized interventions significantly reduced grade 3 or higher chemotherapy-related toxicity among patients with cancer aged 65 years or older, randomized trial results showed. Read more.